Clinical Trials Logo

Tumor Lysis Syndrome clinical trials

View clinical trials related to Tumor Lysis Syndrome.

Filter by:

NCT ID: NCT04745910 Recruiting - Clinical trials for Malignant Solid Neoplasm

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Start date: April 5, 2022
Phase: Phase 4
Study type: Interventional

This trial studies the effect of pegloticase in reducing uric acid levels in patients with hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney function. The goal of this trial is to learn if pegloticase may lower uric acid levels in blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.

NCT ID: NCT03605212 Terminated - Clinical trials for Tumor Lysis Syndrome

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

FLORET
Start date: February 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect in terms of serum uric acid levels.

NCT ID: NCT01724528 Completed - Clinical trials for Tumor Lysis Syndrome

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

FLORENCE
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether febuxostat is superior to allopurinol in the prevention of tumor lysis syndrome (TLS) in patients with hematological malignancies at intermediate or high risk of TLS (according to Cairo-Bishop classification) who undergo chemotherapy

NCT ID: NCT01200485 Completed - Lymphoma Clinical Trials

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Start date: April 2011
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if using Elitek (rasburicase) for 2 cycles can help to control or prevent TLS better than 1 cycle of rasburicase and 1 cycle of allopurinol. The safety of this treatment will also be studied.

NCT ID: NCT01097369 Terminated - Clinical trials for Tumor Lysis Syndrome

Elitek (Rasburicase) Immuno-Monitoring Study

Start date: February 2010
Phase: N/A
Study type: Observational

Primary Objective: To determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.

NCT ID: NCT00651911 Completed - Clinical trials for Tumor Lysis Syndrome

Fasturtec TLS Treatment / Prophylysis

Start date: July 2003
Phase: Phase 4
Study type: Interventional

An open-label study to determine the efficacy and safety of Rasburicase used for the prevention and treatment of tumor lysis syndrome

NCT ID: NCT00628628 Completed - Clinical trials for Tumor Lysis Syndrome

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Start date: January 2008
Phase: Phase 2
Study type: Interventional

Primary Objectives: To determine the efficacy of rasburicase administered as a single dose followed by as needed dosing (investigational arm) as compared to fixed dosing for 5 days (standard treatment arm) in the treatment of patients at high risk or potential risk for tumor lysis syndrome. Secondary Objectives: 1. To evaluate the plasma uric acid area under the curve (AUC) from baseline through 7 days 2. To evaluate the incidence of renal insufficiency and electrolyte abnormalities. 3. To determine the safety and immunogenicity of rasburicase. 4. To evaluate the cost-effectiveness of the experimental treatment (investigational arm).

NCT ID: NCT00563771 Completed - Hyperuricemia Clinical Trials

Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome

Start date: March 2003
Phase: Phase 4
Study type: Interventional

To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia

NCT ID: NCT00360438 Completed - Lymphoma Clinical Trials

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Start date: July 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Primary 1. To determine the pharmacokinetic (PK) parameters of rasburicase in adult patients with leukemia and/or lymphoma at high risk or potential risk of tumor lysis syndrome (TLS) Secondary 1. To evaluate plasma uric acid AUC from baseline (within 4 hours prior to first rasburicase treatment) through 48 hours after the last per-protocol planned administration of rasburicase treatment; 2. To evaluate the safety of rasburicase in adult patients with leukemia and/or lymphoma. 3. To evaluate incidence, duration, and type of immune responses (IgG, IgE, and neutralizing antibody) to rasburicase.

NCT ID: NCT00302653 Completed - Hyperuricemia Clinical Trials

Rasburicase in Tumor Lysis Syndrome

Start date: February 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.